ClinicalTrials.gg
RecruitingNCT06826274AMPLI-MOVUpdated Nov 6, 2026

Cervical tsDCS on Stroke Patients

An interventional study of tDCS in Functional Recovery and Motor Rehabilitation, sponsored by IRCCS San Raffaele Roma. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by IRCCS San Raffaele Roma · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 6, 2026Now RecruitingStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The present project aims to evaluate the facilitatory modulation of motor responses of the limb upper limb by tsDCS in patients with arm/hand hyposthenia after cerebral ischemia to verify the possible therapeutic benefits that this type of stimulation can induce in terms of of strength, dexterity and effectiveness in acts of daily living.

02

Conditions studied

  • Functional Recovery
  • Motor Rehabilitation
03

In context

Lead sponsor

IRCCS San Raffaele Roma is the lead sponsor of 71 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Group Stroke:

Inclusion criteria:

  1. age over 18 years;
  2. first ischemic/hemorrhagic stroke (within 30 days of onset);
  3. mild-to-moderate stroke (NIHSS scale score\<16).
  4. residual function of the upper limb, assessed by the following scales: - MRC of the distal muscles of the upper limb: score between 2 and 4; - NHISS (items 5A and 5B): score between 1 and 3;
  5. ability to give and understand instructions.

Exclusion criteria:

  1. severe spasticity (Ashworth Scale score > 2);
  2. severe aphasia;
  3. severe neglect;
  4. history of disabling neurological disease;
  5. history of epilepsy;
  6. significant comorbidities;
  7. to tsDCS.

Healthy Group:

Inclusion criteria:

  1. age over 18 years;
  2. equalized in age with the patient group.

Exclusion criteria:

  1. history of stroke progress;
  2. history of severe neurological disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Stroke

    Other: tDCS

  • Experimental
    Healthy

    Other: tDCS

Interventions

  • OthertDCS

    Transcranial direct current stimulation

06

What researchers measure

Primary outcomes

  1. improvement of paretic hand performance

    The primary outcome measure is the improvement in hand strength and dexterity in individuals with upper limb motor impairment following cerebral ischemia, after the application of tsDCS at the cervical spinal level during Reaching

    Time frame: through study completion, an average of 1 year

  2. improvement of paretic hand performance

    The primary outcome measure is the improvement in hand strength and dexterity in individuals with upper limb motor impairment following cerebral ischemia, after the application of tsDCS at the cervical spinal level during Grasping

    Time frame: through study completion, an average of 1 year

  3. improvement of paretic hand performance

    The primary outcome measure is the improvement in hand strength and dexterity in individuals with upper limb motor impairment following cerebral ischemia, after the application of tsDCS at the cervical spinal level during Lifting test

    Time frame: through study completion, an average of 1 year

  4. improvement of paretic hand performance

    The primary outcome measure is the improvement in hand strength and dexterity in individuals with upper limb motor impairment following cerebral ischemia, after the application of tsDCS at the cervical spinal level duringthe Nine Hole Peg test

    Time frame: through study completion, an average of 1 year

  5. improvement of paretic hand performance

    The primary outcome measure is the improvement in hand strength and dexterity in individuals with upper limb motor impairment following cerebral ischemia, after the application of tsDCS at the cervical spinal level during finger mobility tests

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Mar 2025 → Mar 2026, primary completion Jan 2026 → Dec 2028 and completion Mar 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 13, 2025
StartActual
Mar 15, 2026was Mar 2025
Primary completionEst.
Dec 31, 2028was Jan 2026
CompletionEst.
Dec 31, 2028was Mar 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
2 sites added, 1 site removed
Show 2 added (2 Italy)
  • IRCCS San Raffaele Roma · Roma, Italy
  • IRCCS San Raffaele Roma · Rome, Italy
Show 1 removed
  • IRCCS San Raffaele Roma · Rome, Italy
Nov 6, 2026
Start date
Mar 2025→Mar 15, 2026 (actual)
Nov 6, 2026
Primary completion
Jan 2026→Dec 31, 2028
Nov 6, 2026
Study completion
Mar 2026→Dec 31, 2028
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    2 sites added, 1 site removed
    Show 2 added (2 Italy)
    • IRCCS San Raffaele Roma · Roma, Italy
    • IRCCS San Raffaele Roma · Rome, Italy
    Show 1 removed
    • IRCCS San Raffaele Roma · Rome, Italy
    Start date Mar 2025→Mar 15, 2026 (now actual)
    Primary completion Jan 2026→Dec 31, 2028
    Study completion Mar 2026→Dec 31, 2028
    + 4 other changes: index terms, identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06826274
Lead sponsor
IRCCS San Raffaele Roma
Responsible party
Sponsor
First posted
Feb 13, 2025
Start date
Mar 15, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Fabrizio Vecchio
Contact
fabrizio.vecchio@sanraffaele.it
3478031201

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion